Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Shaji Kumar, MD, Jesus G. Berdeja, MD, Ruben Niesvizky, MD, Sagar Lonial, MD, Jacob P. Laubach, MD, Mehdi Hamadani, MD, A. Keith Stewart, MD, Parameswaran N. Hari, MD, Vivek Roy, MD, Robert Vescio, MD, Jonathan L. Kaufman, MD, Deborah Berg, RN, MSN, Eileen Liao, PhD, Ai-Min Hui, MD PhD, S. Vincent Rajkumar, MD, Paul G. Richardson

Blood (2014) 124 (21): 82.

https://doi.org/10.1182/blood.V124.21.82.82

Published: 2014

Journal Articles

Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study

Anita D'Souza, MD, Baldeep Wirk, MD, Mei-Jie Zhang, PhD, Jiaxing Huang, MS, Amrita Krishnan, MD, Tomer M Mark, MD MSc, Cristina J. Gasparetto, MD, Parameswaran N. Hari, MD MRCP, MS

Blood (2014) 124 (21): 193.

https://doi.org/10.1182/blood.V124.21.193.193

Published: 2014

Journal Articles

Meta-Analysis of Pharmacotherapy Vs. Observation for Management of Smoldering Multiple Myeloma

Jayanthi Vijayakumar, MBBS, Jeffrey Jackson, MD MPH, Kwang W Ahn, PhD, Parameswaran N. Hari, MD MRCP, MS

Blood (2014) 124 (21): 4771.

https://doi.org/10.1182/blood.V124.21.4771.4771

Published: 2014

Journal Articles

A Statistical Model for Predicting Neutropenic Fever

Ariel Nelson, MD, Dan Eastwood, MS, Tao Wang, PhD, Karen Carlson, MD PhD, Laura C Michaelis, MD, Marcelo C. Pasquini, MD MS, Parameswaran N. Hari, MD, Christopher R. Chitambar, MD, Timothy S. Fenske, MD, Mary Beth Graham, MD, Mehdi Hamadani, MD, Anita D'Souza, MBBS, MD, Ehab Atallah, MD

Blood (2014) 124 (21): 5258.

https://doi.org/10.1182/blood.V124.21.5258.5258

Published: 2014

Journal Articles

Ruxolitinib Prior to Allogeneic Stem Cell Transplantation Does Not Adversely Affect Post-Transplant Outcomes

Ahmad Hanif, MD, Parameswaran N. Hari, MD MRCP, MS, Ehab Atallah, MD, Karen-Sue B. Carlson, MD PhD, Marcelo C. Pasquini, MD, Laura C Michaelis, MD

Blood (2014) 124 (21): 1851.

https://doi.org/10.1182/blood.V124.21.1851.1851

Published: 2014

Journal Articles

Disparities in Utilization of Autologous Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma in the US

Luciano J Costa, MD PhD, Jia-Xing Huang, MS, Parameswaran N. Hari, MD MRCP, MS

Blood (2014) 124 (21): 557.

https://doi.org/10.1182/blood.V124.21.557.557

Published: 2014

Journal Articles

Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation

Luciano J Costa, MD PhD, Geoffrey L. Uy, MD, Parameswaran N. Hari, MD MRCP, MS, Mei-Jie Zhang, PhD, Jiaxing Huang, MS, Amrita Krishnan, MD, Tomer M Mark, MD MSc, Anita D'Souza, MD

Blood (2014) 124 (21): 2447.

https://doi.org/10.1182/blood.V124.21.2447.2447

Published: 2014

Journal Articles

Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study

Parameswaran N. Hari, MD, Kenneth H. Shain, MD PhD, Peter M. Voorhees, MD, Nashat Gabrail, MD, Muneer H. Abidi, MD, Jeffrey Zonder, MD, Ralph V. Boccia, MD, Paul G. Richardson, Linda L. Neuman, MD MBA, Sandra J. Dixon, MS, Claudia Paba Prada, MD

Blood (2014) 124 (21): 3453.

https://doi.org/10.1182/blood.V124.21.3453.3453

Published: 2014

Journal Articles

A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma

Noopur Raje, MD, Parameswaran N. Hari, MD, MRCP, MS, Heather Landau, MD, Paul G. Richardson, MD, Jacalyn Rosenblatt, MD, Nicole Couture, RN, John F. Lyons, PhD, Gillian Langford, PhD, Murray Yule, MD

Blood (2013) 122 (21): 1976.

https://doi.org/10.1182/blood.V122.21.1976.1976

Published: 2013

Journal Articles

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)

Noopur Raje, MD, Dan T. Vogl, MD, MSCE, Parameswaran N. Hari, MD, MRCP, MS, Sundar Jagannath, MD, Simon S Jones, PhD, Jeffrey G Supko, PhD, Gina Leone, RN, Catherine Wheeler, MD, Robert Z. Orlowski, M.D., Ph.D., Paul G. Richardson, MD, Sagar Lonial, M.D.

Blood (2013) 122 (21): 759.

https://doi.org/10.1182/blood.V122.21.759.759

Published: 2013

Journal Articles

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

Noopur Raje, MD, Parameswaran N Hari, MD, MRCP, MS, Dan T. Vogl, MD, MSCE, Sundar Jagannath, MD, Robert Z. Orlowski, M.D., Ph.D., Jeffrey G Supko, PhD, Patricia Stephenson, ScD, Simon S Jones, Catherine Wheeler, MD, Sagar Lonial, MD

Blood (2012) 120 (21): 4061.

https://doi.org/10.1182/blood.V120.21.4061.4061

Published: 2012

Journal Articles

Comparison of Prognostic Models for Autologous Hematopoietic Stem Cell Transplantation (AHCT) for Relapsed Hodgkin Lymphoma.

Theresa Hahn, PhD, Philip L. McCarthy, MD, Jeanette Carreras, MPH, Mei-Jie Zhang, PhD, Hillard M. Lazarus, MD, Ginna G. Laport, MD, Silvia Montoto, MD, Parameswaran N Hari, MD

Blood (2009) 114 (22): 1215.

https://doi.org/10.1182/blood.V114.22.1215.1215

Published: 2009

Journal Articles

HLA-Identical Sibling-Matched, CD34 + Selected, T Cell Depleted Peripheral Blood Stem Cells Following Myeloablative Conditioning for First or Second Remission Acute Myeloid Leukemia (AML): Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303.

Steven M. Devine, MD, Robert J Soiffer, MD, Marcelo C. Pasquini, MD, Shelly Carter, Parameswaran N Hari, MD, MRCP, MS, Stephanie DeVore, Anthony Stein, Hillard M. Lazarus, MD, Charles Linker, MD, Edward A. Stadtmauer, MD, Carolyn A. Keever-Taylor, PhD, Richard J O'Reilly, MD

Blood (2009) 114 (22): 655.

https://doi.org/10.1182/blood.V114.22.655.655

Published: 2009

Journal Articles

Comparison of Unrelated and Sibling Donor Allogeneic Hematopoietic Cell Transplantation (HCT) for Follicular Lymphoma (FL) - From the Lymphoma Working Party, European Group for Blood and Marrow Transplantation (EBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR).

Marcelo C. Pasquini, MD, Mei-Jie Zhang, PhD, Parameswaran N Hari, MD, Silvia Montoto, MD, Ginna G. Laport, MD, Hillard M Lazarus, MD, Michel Attal, MD, Nigel H. Russell, MD, Kristy Thomson, M.D., Jean-Paul Vernant, Carmen Canals, Sr., Harry Schouten, Anna Sureda, MD, PhD

Blood (2009) 114 (22): 874.

https://doi.org/10.1182/blood.V114.22.874.874

Published: 2009

Journal Articles

Alternative Donor Hematopoietic Cell Transplantation (HCT) After Reduced Intensity (RIC) or Nonmyeloablative (NST) Conditioning in Advanced Non-Hodgkin Lymphoma (NHL).

Gregory A. Hale, MD, Smriti Shrestha, MS, MA, Jennifer LeRademacher, PhD, Hillard M Lazarus, MD, Ginna G. Laport, MD, Silvia Montoto, MD, Parameswaran N Hari, MD

Blood (2009) 114 (22): 3380.

https://doi.org/10.1182/blood.V114.22.3380.3380

Published: 2009

Journal Articles

High Prevalence of Dapsone-Induced Oxidant Hemolysis in North American Stem Cell Transplant Recipients without Glucose-6-Phosphate-Dehydrogenase Deficiency.

Horatiu Olteanu, MD, PhD, Alexandra Harrington, MD, Ben George, MD, Christopher Bredeson, MD, Parameswaran N. Hari, MD, MS, Steven Kroft, MD

Blood (2009) 114 (22): 3314.

https://doi.org/10.1182/blood.V114.22.3314.3314

Published: 2009

Journal Articles

An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma.

Noopur Raje, MD., Paul Richardson, M.D., Parameswaran N Hari, MD, Anuj Mahindra, Sarah Kaster, BS, Christine Connolly, Linda Rivera, Gaurav Chetri, Sarah Dean, Paulette Jacobs, Ayman Saad, MD, Jacob Laubach, Irene M. Ghobrial, M.D., Robert L Schlossman, M.D., Ph.D., Jennifer Adams, Wendy Makrides, Edie Weller, PhD, Nikhil Munshi, M.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3856.

https://doi.org/10.1182/blood.V114.22.3856.3856

Published: 2009

Journal Articles

Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis.

Parameswaran N Hari, MD, A. John Barrett, MD, Smriti Shrestha, MS, MA, Gisela Tunes da Silva, PhD, Mei-Jie Zhang, PhD, Angela Dispenzieri, MD, Gustavo A. Milone, MD, Sagar Lonial, MD, Olle Ringden, MD

Blood (2009) 114 (22): 53.

https://doi.org/10.1182/blood.V114.22.53.53

Published: 2009

Journal Articles

Hypomethylating Agent Therapy for Acute Myelogenous Leukemia (AML) Can Induce Sustained Responses with Low Induction Mortality.

Jasleen K Randhawa, MD, Christopher Bredeson, MD, Timothy S. Fenske, MD, Ayman Saad, MD, Jeanne Palmer, MD, Parameswaran N Hari, MD, Horatiu Olteanu, Ehab Atallah, MD

Blood (2009) 114 (22): 4157.

https://doi.org/10.1182/blood.V114.22.4157.4157

Published: 2009

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience.

Anuj Mahindra, MD, David Vesole, MD, PhD, Matt E. Kalaycio, MD, Jorge Vela-Ojeda, MD, Smriti Shrestha, MS, MA, Mei-Jie Zhang, PhD, Angela Dispenzieri, MD, Gustavo A. Milone, MD, Sagar Lonial, MD, Parameswaran N. Hari, MD, MS

Blood (2009) 114 (22): 532.

https://doi.org/10.1182/blood.V114.22.532.532

Published: 2009

NARROW

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study

Meta-Analysis of Pharmacotherapy Vs. Observation for Management of Smoldering Multiple Myeloma

A Statistical Model for Predicting Neutropenic Fever

Ruxolitinib Prior to Allogeneic Stem Cell Transplantation Does Not Adversely Affect Post-Transplant Outcomes

Disparities in Utilization of Autologous Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma in the US

Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation

Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study

A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

Comparison of Prognostic Models for Autologous Hematopoietic Stem Cell Transplantation (AHCT) for Relapsed Hodgkin Lymphoma.

HLA-Identical Sibling-Matched, CD34 + Selected, T Cell Depleted Peripheral Blood Stem Cells Following Myeloablative Conditioning for First or Second Remission Acute Myeloid Leukemia (AML): Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303.

Comparison of Unrelated and Sibling Donor Allogeneic Hematopoietic Cell Transplantation (HCT) for Follicular Lymphoma (FL) - From the Lymphoma Working Party, European Group for Blood and Marrow Transplantation (EBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR).

Alternative Donor Hematopoietic Cell Transplantation (HCT) After Reduced Intensity (RIC) or Nonmyeloablative (NST) Conditioning in Advanced Non-Hodgkin Lymphoma (NHL).

High Prevalence of Dapsone-Induced Oxidant Hemolysis in North American Stem Cell Transplant Recipients without Glucose-6-Phosphate-Dehydrogenase Deficiency.

An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma.

Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis.

Hypomethylating Agent Therapy for Acute Myelogenous Leukemia (AML) Can Induce Sustained Responses with Low Induction Mortality.

Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only